Clinical Trial

Fecal Lactate and Resuscitation Outcomes in Critical Illness

Study acronym: DELTA-LAC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study evaluates the prognostic value of fecal lactate and the fecal-to-serum lactate gradient as early biomarkers of tissue hypoperfusion in critically ill patients. While serum lactate is widely used, it may not accurately reflect splanchnic perfusion. This prospective observational study aims to determine whether fecal lactate levels obtained within the first 12-24 hours can predict poor response to resuscitation at 24 hours. The primary outcome is a composite of increased vasopressor requirements, persistent hyperlactatemia, worsening organ dysfunction, or death.
Trial Details
NCT Number NCT07658001
Lead Sponsor Hospital H+ Queretaro
Conditions Tissue Hypoperfusion, Critical Illness, Shock, Sepsis
Enrollment 40 participants
Start Date 2026-04-06
Primary Completion 2026-11-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29